ID   ZN629_HUMAN             Reviewed;         869 AA.
AC   Q9UEG4; Q15938;
DT   20-MAR-2007, integrated into UniProtKB/Swiss-Prot.
DT   20-MAR-2007, sequence version 2.
DT   03-MAY-2023, entry version 165.
DE   RecName: Full=Zinc finger protein 629;
DE   AltName: Full=Zinc finger protein 65;
GN   Name=ZNF629; Synonyms=KIAA0326, ZNF65;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 147-255.
RC   TISSUE=Placenta;
RX   PubMed=1946370; DOI=10.1073/pnas.88.21.9563;
RA   Bray P.L., Lichter P., Thiesen H.-J., Ward D.C., Dawid I.B.;
RT   "Characterization and mapping of human genes encoding zinc finger
RT   proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:9563-9567(1991).
RN   [3]
RP   IDENTIFICATION.
RX   PubMed=1505991; DOI=10.1016/0888-7543(92)90013-i;
RA   Lichter P., Bray P., Ried T., Dawid I.B., Ward D.C.;
RT   "Clustering of C2-H2 zinc finger motif sequences within telomeric and
RT   fragile site regions of human chromosomes.";
RL   Genomics 13:999-1007(1992).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-616, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18 AND SER-616, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [7]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-688 AND LYS-840, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [8]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-251; LYS-688; LYS-750 AND
RP   LYS-840, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: May be involved in transcriptional regulation.
CC   -!- INTERACTION:
CC       Q9UEG4; Q8TD31-3: CCHCR1; NbExp=3; IntAct=EBI-9977294, EBI-10175300;
CC       Q9UEG4; Q86X02: CDR2L; NbExp=3; IntAct=EBI-9977294, EBI-11063830;
CC       Q9UEG4; O95995: GAS8; NbExp=3; IntAct=EBI-9977294, EBI-1052570;
CC       Q9UEG4; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-9977294, EBI-5916454;
CC       Q9UEG4; Q14541-2: HNF4G; NbExp=3; IntAct=EBI-9977294, EBI-18543805;
CC       Q9UEG4; Q9ULR0-1: ISY1; NbExp=3; IntAct=EBI-9977294, EBI-18398632;
CC       Q9UEG4; O75564-2: JRK; NbExp=3; IntAct=EBI-9977294, EBI-17181882;
CC       Q9UEG4; O95751: LDOC1; NbExp=3; IntAct=EBI-9977294, EBI-740738;
CC       Q9UEG4; P36873: PPP1CC; NbExp=3; IntAct=EBI-9977294, EBI-356283;
CC       Q9UEG4; Q9UHP6: RSPH14; NbExp=3; IntAct=EBI-9977294, EBI-748350;
CC       Q9UEG4; Q96GM5: SMARCD1; NbExp=3; IntAct=EBI-9977294, EBI-358489;
CC       Q9UEG4; Q9NZD8: SPG21; NbExp=3; IntAct=EBI-9977294, EBI-742688;
CC       Q9UEG4; Q96N21: TEPSIN; NbExp=3; IntAct=EBI-9977294, EBI-11139477;
CC       Q9UEG4; Q8WV44: TRIM41; NbExp=3; IntAct=EBI-9977294, EBI-725997;
CC       Q9UEG4; P13994: YJU2B; NbExp=3; IntAct=EBI-9977294, EBI-716093;
CC       Q9UEG4; Q7Z4V0: ZNF438; NbExp=3; IntAct=EBI-9977294, EBI-11962468;
CC       Q9UEG4; Q9Y2P0: ZNF835; NbExp=3; IntAct=EBI-9977294, EBI-5667516;
CC       Q9UEG4; Q9UGI0: ZRANB1; NbExp=3; IntAct=EBI-9977294, EBI-527853;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the krueppel C2H2-type zinc-finger protein
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA20784.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB002324; BAA20784.1; ALT_INIT; mRNA.
DR   EMBL; M88374; AAA61332.1; -; Genomic_DNA.
DR   CCDS; CCDS45463.1; -.
DR   PIR; H45193; H45193.
DR   RefSeq; NP_001073886.1; NM_001080417.2.
DR   RefSeq; NP_001332899.1; NM_001345970.1.
DR   AlphaFoldDB; Q9UEG4; -.
DR   SMR; Q9UEG4; -.
DR   BioGRID; 116942; 122.
DR   IntAct; Q9UEG4; 30.
DR   MINT; Q9UEG4; -.
DR   STRING; 9606.ENSP00000262525; -.
DR   iPTMnet; Q9UEG4; -.
DR   PhosphoSitePlus; Q9UEG4; -.
DR   BioMuta; ZNF629; -.
DR   DMDM; 134035371; -.
DR   EPD; Q9UEG4; -.
DR   jPOST; Q9UEG4; -.
DR   MassIVE; Q9UEG4; -.
DR   MaxQB; Q9UEG4; -.
DR   PaxDb; Q9UEG4; -.
DR   PeptideAtlas; Q9UEG4; -.
DR   ProteomicsDB; 84146; -.
DR   Antibodypedia; 7095; 12 antibodies from 7 providers.
DR   DNASU; 23361; -.
DR   Ensembl; ENST00000262525.6; ENSP00000262525.4; ENSG00000102870.6.
DR   GeneID; 23361; -.
DR   KEGG; hsa:23361; -.
DR   MANE-Select; ENST00000262525.6; ENSP00000262525.4; NM_001080417.3; NP_001073886.1.
DR   UCSC; uc002dzs.1; human.
DR   AGR; HGNC:29008; -.
DR   CTD; 23361; -.
DR   DisGeNET; 23361; -.
DR   GeneCards; ZNF629; -.
DR   HGNC; HGNC:29008; ZNF629.
DR   HPA; ENSG00000102870; Low tissue specificity.
DR   MIM; 619587; gene.
DR   neXtProt; NX_Q9UEG4; -.
DR   OpenTargets; ENSG00000102870; -.
DR   PharmGKB; PA134930939; -.
DR   VEuPathDB; HostDB:ENSG00000102870; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000161909; -.
DR   HOGENOM; CLU_002678_17_1_1; -.
DR   InParanoid; Q9UEG4; -.
DR   OMA; FKMPEGQ; -.
DR   OrthoDB; 4621679at2759; -.
DR   PhylomeDB; Q9UEG4; -.
DR   TreeFam; TF350847; -.
DR   PathwayCommons; Q9UEG4; -.
DR   SignaLink; Q9UEG4; -.
DR   BioGRID-ORCS; 23361; 54 hits in 1178 CRISPR screens.
DR   ChiTaRS; ZNF629; human.
DR   GenomeRNAi; 23361; -.
DR   Pharos; Q9UEG4; Tdark.
DR   PRO; PR:Q9UEG4; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q9UEG4; protein.
DR   Bgee; ENSG00000102870; Expressed in tendon of biceps brachii and 195 other tissues.
DR   Genevisible; Q9UEG4; HS.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 18.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR24381; ZINC FINGER PROTEIN; 1.
DR   PANTHER; PTHR24381:SF413; ZINC FINGER PROTEIN 436; 1.
DR   Pfam; PF00096; zf-C2H2; 14.
DR   SMART; SM00355; ZnF_C2H2; 19.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 13.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 19.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 19.
PE   1: Evidence at protein level;
KW   DNA-binding; Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..869
FT                   /note="Zinc finger protein 629"
FT                   /id="PRO_0000280426"
FT   ZN_FING         150..172
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         178..200
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         206..228
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         234..256
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         262..284
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         290..312
FT                   /note="C2H2-type 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         318..340
FT                   /note="C2H2-type 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         346..368
FT                   /note="C2H2-type 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         374..396
FT                   /note="C2H2-type 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         402..424
FT                   /note="C2H2-type 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         430..452
FT                   /note="C2H2-type 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         458..480
FT                   /note="C2H2-type 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         486..508
FT                   /note="C2H2-type 13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         514..536
FT                   /note="C2H2-type 14"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         569..591
FT                   /note="C2H2-type 15"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         662..684
FT                   /note="C2H2-type 16"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         714..736
FT                   /note="C2H2-type 17"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         768..790
FT                   /note="C2H2-type 18"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         842..864
FT                   /note="C2H2-type 19"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          1..105
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          607..651
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          787..837
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        22..39
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        811..832
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         18
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         616
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   CROSSLNK        251
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        688
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        750
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        840
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   VARIANT         707
FT                   /note="P -> A (in dbSNP:rs8050758)"
FT                   /id="VAR_052883"
SQ   SEQUENCE   869 AA;  96620 MW;  A3C1B86589BD57F5 CRC64;
     MEPETALWGP DLQGPEQSPN DAHRGAESEN EEESPRQESS GEEIIMGDPA QSPESKDSTE
     MSLERSSQDP SVPQNPPTPL GHSNPLDHQI PLDPPAPEVV PTPSDWTKAC EASWQWGALT
     TWNSPPVVPA NEPSLRELVQ GRPAGAEKPY ICNECGKSFS QWSKLLRHQR IHTGERPNTC
     SECGKSFTQS SHLVQHQRTH TGEKPYKCPD CGKCFSWSSN LVQHQRTHTG EKPYKCTECE
     KAFTQSTNLI KHQRSHTGEK PYKCGECRRA FYRSSDLIQH QATHTGEKPY KCPECGKRFG
     QNHNLLKHQK IHAGEKPYRC TECGKSFIQS SELTQHQRTH TGEKPYECLE CGKSFGHSST
     LIKHQRTHLR EDPFKCPVCG KTFTLSATLL RHQRTHTGER PYKCPECGKS FSVSSNLINH
     QRIHRGERPY ICADCGKSFI MSSTLIRHQR IHTGEKPYKC SDCGKSFIRS SHLIQHRRTH
     TGEKPYKCPE CGKSFSQSSN LITHVRTHMD ENLFVCSDCG KAFLEAHELE QHRVIHERGK
     TPARRAQGDS LLGLGDPSLL TPPPGAKPHK CLVCGKGFND EGIFMQHQRI HIGENPYKNA
     DGLIAHAAPK PPQLRSPRLP FRGNSYPGAA EGRAEAPGQP LKPPEGQEGF SQRRGLLSSK
     TYICSHCGES FLDRSVLLQH QLTHGNEKPF LFPDYRIGLG EGAGPSPFLS GKPFKCPECK
     QSFGLSSELL LHQKVHAGGK SSQKSPELGK SSSVLLEHLR SPLGARPYRC SDCRASFLDR
     VALTRHQETH TQEKPPNPED PPPEAVTLST DQEGEGETPT PTESSSHGEG QNPKTLVEEK
     PYLCPECGAG FTEVAALLLH RSCHPGVSL
//
